Psychedelics Investing News, Stocks, Forecasts and Analysis

Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

As federal policies shift, the psychedelic medicine market is transitioning from speculative research to a prescription-oriented framework. Could 2026 be a breakthrough year for psychedelic therapies?

Psychedelics Investing

Investing News NetworkYour trusted source for investing success

Psychedelics Investing

Psychedelics Market Trends: H1 2026 Review and Forecast

Eli Lilly to Buy Psychedelics Firm AtaiBeckley for US$2.8 Billion

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

Psychedelics Market Forecast: Top Trends for Psychedelics in 2026

Psychedelics Market Update: H1 2025 in Review

US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025

SVN-114 selected as the lead candidate for PTSD discovery programme

Lobe Sciences Reports First Quarter 2026 Results and Highlights

Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

U.S. Patent allowance received for PTSD discovery programme

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302

Fungtional Labs: Integrated Supply Chain for Mushroom Cultivators in North America

Lobe Sciences Provides Update on L-130 Clinical Program

Emyria Launches Global Services Platform Targeting International Drug Sponsors

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Quarterly Activities Report: Melodiol Delivers $9.3m in Revenue During H1 FY24 – a 33% Increase the PCP

Psychedelics Market Forecast: Top Trends for Psychedelics in 2025

Psychedelics Market Update: H1 2024 in Review

Psychedelics Market Forecast: Top Trends That Will Affect Psychedelics in 2024

Latest psychedelics News

Outlook Reports world

Featured Psychedelics Investing Stocks

Melodiol Global Health

Reunion Neuroscience

Lucy Scientific Discovery

Irwin Naturals

COMPASS Pathways Plc

Albert Labs

Browse Companies